Contrasting Allergy Therapeutics (OTCMKTS:AGYTF) and Avalo Therapeutics (NASDAQ:AVTX)

Avalo Therapeutics (NASDAQ:AVTX) and Allergy Therapeutics (OTCMKTS:AGYTF) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, profitability and valuation.

Earnings and Valuation

This table compares Avalo Therapeutics and Allergy Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalo Therapeutics	$59,000.00	14,567.02	-$78.26 million	($5.46)	-2.99
Allergy Therapeutics	$71.22 million	1.06	-$51.94 million	N/A	N/A

Allergy Therapeutics has higher revenue and earnings than Avalo Therapeutics.

Profitability

This table compares Avalo Therapeutics and Allergy Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Avalo Therapeutics	N/A	-97.54%	-72.42%
Allergy Therapeutics	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of current ratings and price targets for Avalo Therapeutics and Allergy Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalo Therapeutics	1	0	11	0	2.83
Allergy Therapeutics	0	0	0	0	0.00

Avalo Therapeutics presently has a consensus target price of $48.13, suggesting a potential upside of 194.34%. Given Avalo Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Avalo Therapeutics is more favorable than Allergy Therapeutics.

Insider and Institutional Ownership

87.1% of Avalo Therapeutics shares are held by institutional investors. 4.5% of Avalo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Risk & Volatility

Avalo Therapeutics has a beta of 0.78, meaning that its stock price is 22% less volatile than the S&P 500. Comparatively, Allergy Therapeutics has a beta of 12.76, meaning that its stock price is 1,176% more volatile than the S&P 500.

Summary

Avalo Therapeutics beats Allergy Therapeutics on 6 of the 11 factors compared between the two stocks.

About Avalo Therapeutics

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

About Allergy Therapeutics

Allergy Therapeutics plc engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, Acarovac MPL, Venomil, Synbiotics, Penicillin Diagnostics, and Peanut. The company also develops allergy vaccines for grass, tree, and house dust mite, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.